CAMBRIDGE, Mass.--(BUSINESS WIRE)--Navitor Pharmaceuticals, Inc., a biopharmaceutical company targeting the mTORC1 pathway to develop novel therapeutics that help patients live longer and healthier lives, announced today the initiation of a Phase 1 clinical study with its lead pipeline candidate, NV-5138, for treatment-resistant depression (TRD). NV-5138 is a novel small molecule that directly activates mTORC1, a master cellular regulator that has recently been shown to be a central signaling pathway required for the efficacy of several rapid acting antidepressants. NV-5138 is initially being evaluated in TRD but may offer future potential for the treatment in the broader disease category of major depressive disorder (MDD).
“We are enthusiastic about initiating clinical development with NV-5138 for major depressive disorder, as we believe this novel activator of mTORC1 has the potential to offer a unique approach to meeting many of the unmet needs of this serious and chronic disease. Millions of patients with depression do not adequately respond to standard pharmacological therapies which can take weeks or months before patients experience their effects, if at all,” said George P. Vlasuk, PhD, President and Chief Executive Officer of Navitor. “We see the development of NV-5138 in MDD/TRD as a pioneering advance toward realizing the therapeutic potential of modulating the mTORC1 signaling pathway to treat a wide range of chronic human diseases.”
The Phase 1, multicenter, two-part, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of NV-5138 in up to 88 subjects, including healthy volunteers and patients diagnosed with TRD. In Part A, the single-ascending-dose portion of the study, up to 48 healthy volunteers will be randomly assigned to double-blind treatment in six dosage-level cohorts. Within each cohort, six subjects will be randomized to receive NV-5138 and two subjects will be randomized to receive placebo. In Part B of the study, approximately 40 subjects diagnosed with TRD will be randomly assigned to double-blind treatment at a single dosage level that will be established based on data from Part A of the study. Other prespecified outcome measures to be evaluated in Part B include standard depression rating and symptomology scores such as the Montgomery-Åsberg Depression Rating Scale (MADRS).
“Initiation of this clinical study is supported by preclinical studies demonstrating the potential of NV-5138 as an oral treatment for depression through activation of mTORC1, a cellular pathway that appears to underlie the beneficial effects of several in a new class of rapidly acting antidepressants,” said Maurizio Fava, MD, Director of the Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute and member of the Navitor Clinical Advisory Board.
Previously, Navitor has presented preclinical results on the efficacy of NV-5138 in multiple models of depression-like behavior, which demonstrated that NV-5138 produced behavioral responses and concomitant increases in new synapses (synaptogenesis) consistent with a rapid-acting antidepressant through transient, direct activation of the mTORC1 signaling pathway in the brain. Navitor leveraged multiple preclinical observations that have shown mTORC1 activation is required for the efficacy of many rapid-acting antidepressant compounds including several modulators of the NMDA (N-methyl-D-aspartic acid)-mediated signaling pathway like ketamine, which is an active area of innovative drug development for depression.1,2
About Treatment Resistant Depression and Treatment Options
Treatment-resistant
depression (TRD) is a subset of major depressive disorder (MDD) that
refers to depressive episodes that are not adequately controlled by
standard antidepressant therapy. Several studies including a postmortem
analysis of healthy and severely depressed patients as well as multiple
pre-clinical settings have suggested an association between the activity
of mTORC1 pathway signaling and depression. Standard antidepressant
therapies, such as selective serotonin reuptake inhibitors (SSRIs) and
serotonin and norepinephrine reuptake inhibitors (SNRIs) are only
modestly effective and have a very slow onset typically taking 6-8 weeks
to show efficacy. Newer drugs that antagonize or otherwise modulate the
presynaptic glutamate N-methyl-D-aspartic acid (NMDA) receptor, have
demonstrated the potential for improved efficacy with a rapid onset of
antidepressant effects (days as opposed to weeks) and today there are
several NMDA modulators in clinical development for depression,
including ketamine and related agents. Unfortunately, presynaptic NMDA
receptor modulation can cause significant side effects including
dissociation (hallucination) and has abuse potential.
About Rapid Acting Antidepressants and mTORC1 Activity
New
antidepressant drugs that modulate the presynaptic glutamate
N-methyl-D-aspartic acid (NMDA) receptor, have demonstrated the
potential for improved efficacy with a rapid onset of antidepressant
effects (days as opposed to weeks) and today there are several NMDA
modulators in clinical development for depression, including ketamine
and related agents. Since the initial observations connecting NMDA
receptor modulation and depression, scientists have demonstrated that
these agents increase production of key synaptic signaling proteins
resulting in synaptogenesis and have also elucidated the mechanism that
underlies the therapeutic antidepressant benefit seen with these agents
in specific pre-clinical settings. This new research demonstrates that
presynaptic NMDA receptor modulation transiently activates the
postsynaptic mTORC1 signaling pathway and this activation is required to
initiate the cellular processes like protein synthesis that lead to the
synaptogenesis and antidepressant effects of these agents. Although the
initial target engagement of these agents occurs within a short time
frame of a few hours, this transient activation of mTORC1 results in
sustained, long-lasting synaptic and behavioral effects that persist for
days to even weeks after a single treatment.
About NV-5138
NV-5138 is an orally bioavailable, small
molecule that is designed to directly and transiently activate mTORC1
activity by binding to and modulating a newly discovered cellular sensor
protein for the amino acid leucine, which is a potent natural activator
of mTORC1. Unlike leucine, oral administration of NV-5138 results in
significant mTORC1 pathway activation in the brain since it is not
broken down or incorporated into new proteins. These properties make
NV-5138 a unique agent with which to evaluate the role of mTORC1 in
brain disorders, such as depression, where mTORC1 activity is often
suppressed. Results from preclinical models demonstrate that NV-5138
produces rapid upregulation of key synaptic proteins, synaptogenesis and
sustained antidepressant behavioral responses via the transient and
direct activation of the mTORC1 signaling pathway. Since NV-5138 does
not directly modulate the NMDA receptor pathway, it may not have the
side effects and abuse potential observed with several NMDA receptor
therapeutics currently in development. NV-5138 is currently being
clinically studied for the treatment of major depressive disorder (MDD)
with an initial focus on treatment-resistant depression (TRD).
About Navitor
Navitor Pharmaceuticals, Inc. is realizing the
potential of modulating mTORC1, the master regulator of cellular
function, to develop a pipeline of therapeutics that help patients live
longer and healthier lives. Our industry leading team is unlocking the
promise of recent discoveries in mTORC1 biology to address a broad range
of chronic diseases. Our initial clinical application is a
first-in-class drug to address unmet needs in depression. For more
information, please visit www.navitorpharma.com.
1. Duman, RS and Aghajanian, GK. Science. 2012 October 5; 338(6103): 68–72.
2. Scheung, L, et al., Frontiers in Neuroscience. 2015 July 21; 9 (249).
